Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

Four months after ditching its lead drug, a small Peninsula biotech with less than $40 million on hand hopes to rev up ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time to buy.

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other ...

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...

StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating in a report issued on Tuesday. Other analysts also recently issued research ...

San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other most profitable biotech stocks to buy right now. With improved market ...